Pairing two molecules blocks Alzheimer's enzyme better than any single drug.

Alzheimer's disease causes memory loss and cognitive decline, and existing therapies cannot halt or reverse its progression. Drugs targeting BACE1, an enzyme that helps form amyloid plaques, have struggled in clinical trials due to side effects and low efficacy. Researchers explored whether combining two drug molecules could work better together. They filtered a library of small molecules and used a computer simulation method called multi-ligand simultaneous docking, which models how two molecules attach to the target enzyme at the exact same time. First, they tested single molecules to see how each interacted with BACE1. Then, they simulated pairs. The researchers discovered four pairs that bound far more strongly to the enzyme than phase-III trial drugs like Verubecestat and Lanabecestat. These winning pairs also interacted with each other, showing a synergistic effect where both molecules cooperate to stick more tightly to the enzyme.

Why it matters

Alzheimer's disease affects millions and currently has no disease-modifying treatment. This research suggests that combining two small molecules could inhibit the key enzyme BACE1 more effectively than the best single drugs in clinical trials. If confirmed, it could lead to combination therapies that slow or halt disease progression, offering real hope to patients and families.

Questions answered